SCHEMBL4607546

SCHEMBL4607546

O=C1c2ccccc2C(=O)N1[C@@H]1CCC[C@@H]1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
SMO Q99835 1/20 0.43
SLC18A3 Q16572 1/20 0.42
OPRM1 P35372 5/20 0.41
ALDH1A1 P00352 3/20 0.41
CHRM2 P08172 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
CYP1A2 P05177 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SLC6A9 P48067 8/20 0.41
SLC6A5 Q9Y345 3/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607545 1.00 SCN1A (0.44) SCN1ASCN2ASCN3ASMOSLC18A3
SCHEMBL4607494 0.89 MEN1 (0.45) ALDH1A1SLC6A9SLC6A5KDM4E
SCHEMBL4607495 0.89 MEN1 (0.45) ALDH1A1SLC6A9SLC6A5KDM4E
SCHEMBL25341814 0.87 RAB9A (0.44) OPRM1ALDH1A1CYP1A2TSHRSLC6A9
SCHEMBL28817077 0.87 MEN1 (0.44) OPRM1ALDH1A1CHRM2DDB1CRBN
SCHEMBL28817110 0.87 MEN1 (0.44) OPRM1ALDH1A1CHRM2DDB1CRBN
SCHEMBL4607816 0.87 MEN1 (0.44) OPRM1ALDH1A1CHRM2DDB1CRBN
SCHEMBL31330266 0.84 KDM1A (0.43) ALDH1A1DDB1CRBNTSHRTDP1
SCHEMBL1720667 0.82 SMO (0.56) SMOOPRM1ALDH1A1CHRM2DDB1
SCHEMBL1720311 0.82 SMO (0.56) SMOOPRM1ALDH1A1CHRM2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246797-B1 CYCLOPENTYL SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2008-07-23 EP disclosed
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
US-6639107-B1 Potentiating glutamate receptor function ELI LILLY AND COMPANY 2003-10-28 US disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed
EP-1246797-A1 CYCLOPENTYL SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-10-09 EP disclosed
WO-2001042203-A1 CYCLOPENTYL SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 SCN1A 32/4885SCN2A 65/4885SCN3A 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.